Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill
This article was originally published in The Pink Sheet Daily
Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.
You may also be interested in...
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
Addiction prevention legislation empowers Medicare drug plans to restrict prescriber, pharmacy access to opioids for ‘at risk’ beneficiaries.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.